CADTH Canadian Drug Expert Committee recommendation. Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis.

CADTH Canadian Drug Expert Committee recommendation. indication : giant cell arteritis. Tocilizumab (Actemra - Hoffmann-La Roche Limited) :

The CADTH Canadian Drug Expert Committee (CDEC) recommends that tocilizumab be reimbursed for the treatment of giant cell arteritis (GCA) in adult patients, if the following criteria and conditions are met. At initiation of therapy, or with relapse, patients should be receiving prednisone. Duration...

Full description

Saved in:

Bibliographic Details
Online Access:	http://www.ncbi.nlm.nih.gov/books/NBK533005/ Full text
Corporate Author:	CADTH Canadian Drug Expert Committee (Author)
Format:	Electronic eBook
Language:	English
Published:	Ottawa (ON) : CADTH, 2018
Edition:	Final.
Series:	Common drug review clinical review report.
Subjects:	Giant Cell Arteritis > drug therapy. Antibodies, Monoclonal, Humanized > therapeutic use. Antibodies, Monoclonal, Humanized > economics. Drug Costs. Insurance, Health, Reimbursement. Canada.

Clinical review report. Tocilizumab (Actemra) (Hoffmann-La Roche Limited).

Published 2018

Get full text
Full text

Electronic eBook

CADTH Canadian Drug Expert Committee recommendation. indication : giant cell arteritis. Tocilizumab (Actemra - Hoffmann-La Roche Limited) :

Clinical review report. Tocilizumab (Actemra) (Hoffmann-La Roche Limited).

Similar Items